Circulating Tumor Cell (CTC) Diagnostics: Market Research Report

December 2017 | 187 pages | ID: C10843E873AEN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Circulating Tumor Cell (CTC) Diagnostics in US$. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 48 companies including many key and niche players such as -

• ApoCell, Inc.
• Biocep Ltd.
• Biocept, Inc.
• Biofluidica Microtechnologies LLC
• Celltraffix Inc.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Market Outlook
Clinical Relevance of CTCs
CTC Detection – Real-Time ‘Liquid Biopsy’ Scores Over Surgical Biopsy
Major Challenges in CTC Diagnostics
Need for CTC Enrichment and Popular Methods
CTC Enrichment Techniques
Select Available CTC Detection Technologies
Select CTC Isolation Systems – A Brief Comparison
CTC Identification – Various Approaches
CTC Identification Approaches
List of mRNA Markers for RT-PCR–based Detection of CTCs by Tumor Type
CellSearch System – The First FDA Approved Automated Enrichment/Isolation Technique
Rising Incidence of Cancer – An Opportunity Indicator

Table 1. Worldwide Incidence of Cancer (2013, 2020 & 2030): Number of New Cases Diagnosed (includes corresponding Graph/Chart)

Table 2. New Cancer Cases in the World by Affected Site (2012) (In Thousands) (includes corresponding Graph/Chart)

Cancer Prone Sites based on Age

2. MARKET TRENDS AND DRIVERS

Liquid Biopsy – the New Buzzword in Healthcare
Select Companies Active in Cancer Liquid Biopsy
CTCs for Personalized Cancer Treatment
Microfluidic Chip-based Technologies – A Promising Avenue for Cancer Diagnosis
CTC Microdevices Hog the Limelight

Table 3. Select CTC Microdevices and Their Characteristics

Increasing Research Reveal Further Complexities to CTC Composition and Behavior
EpCAM Glycoprotein – Insufficient for CTC Detection
New Isolation Techniques Show Promise in Detecting EpCAM-Negative CTCs
Physical Property-based Enrichment Technologies Lose Fizz
Evidence in Favor CTC Heterogeneity Gains Strength
CTC Clusters Raise Research Interest
Detection of EMTs Gains Precedence in the Backdrop of Recent Research Findings
Limitations of CTC Technology for Point-of- Care Testing
CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis
Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?
Select Research Findings in Recent Years
Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity
NBiomics Makes its Contribution to CTC Diagnosis
Researchers at University of Michigan Develop Revolutionary Capture CTCs Method
Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis
Gold Nanoparticles Help in the Detection of CTCs

3. MEDICAL DIAGNOSTICS MARKET – A CONCEPTUAL OVERVIEW

Clinical Diagnostics

Table 4. Leading Players in the Global In Vitro Diagnostics (IVD) Market (2013) - Market Share Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Siemens, J&J, Beckman Coulter, bioMerieux, and Others (includes corresponding Graph/Chart)

Table 5. Global In-Vitro Diagnostics (IVD) Market (2013): Percentage Breakdown for Value Sales by Segment for Point of Care, Immunity Tests, Clinical Chemistry, Nucleic Acid Tests, Histology/Cytology, Microbiology, Haematology and Others (includes corresponding Graph/Chart)

Molecular Diagnostics – Growth Drivers
Molecular Diagnostics for Lymphoid Malignancies
Market Trends & Issues
Global Molecular Diagnostics on a High Growth Curve
Automation Driving Global Market
Molecular Diagnostics: Marking Convergence of Numerous Technologies
Aging Population, Disease Incidence – Fundamental Drivers of Growth
Pharmaceutical Firms Carving their Niche in the Molecular Diagnostics Market
Limited Reimbursements by Third Party Payers – A Stumbling Block
Molecular Diagnostics and Intellectual Property
Business Opportunities in the Offing
Medical Training and Practice Challenges
Hurdles All the Way for Companies Eyeing Molecular Diagnostics
Integration of Molecular Diagnostics into Therapeutics
Molecular Diagnostics – Moving from Centralization to Decentralization

4. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS – ENRICHMENT, IDENTIFICATION AND CHARACTERIZATION METHODS

5. PRODUCT LAUNCHES AND INTRODUCTIONS

Vortex Biosciences Launches VTX-1 Liquid Biopsy System
Vortex Biosciences Secures CE Mark and FDA Class I Registration for VTX-1 Liquid Biopsy System
Fluxion Biosciences Roll Out New CTC Recovery Kits
Biocept Launches c-MET Amplification Detection Test
Biocept Launches ROS1 Test for Identifying Suitable Therapeutic Targets for NSCLC

6. RECENT INDUSTRY ACTIVITY

Menarini-Silicon Inks Agreement to Take Over CELLSEARCH CTC Assets
Cancer Genetics and ApoCell Team Up for Cancer Profiling and Therapy Selection
Genomic Health Signs Commercial Agreement with Epic Sciences for AR-V7 Liquid Biopsy Test
BGI Joins Hands with Clearbridge BioMedics to Market CTC Products in China
Abnova Secures License to CSV Monoclonal Antibody for CTC Detection
Sorrento Secures License to CytoLumina’s NanoVelcro CTC Profiling Assay
Janssen Announces Utility of CELLSEARCH System in PD-L1 Expression Detection on CTCs
Qiagen Acquires AdnaGen’s CTC Enrichment Technology
Tokai Inks Deal with Qiagen for Licensing CTC Enrichment Technology
ScreenCell Enters Collaborative Study for Evaluating CTC Enrichment Capability of ScreenCell Products

7. FOCUS ON SELECT PLAYERS

ApoCell, Inc. (US)
Biocep Ltd. (Israel)
Biocept, Inc. (US)
Biofluidica Microtechnologies LLC (US)
Celltraffix Inc. (US)
Clearbridge Biomedics (Singapore)
Creatv Microtech, Inc. (US)
Cynvenio Biosystems, Inc. (US)
Epic Biosciences Inc. (US)
Fluxion Biosciences, Inc. (US)
Ikonisys, Inc. (US)
IVDiagnostics, Inc. (US)
Janssen Diagnostics LLC (US)
QIAGEN Hannover GmbH (Germany)
RARECELLS SAS (Italy)
ScreenCell (France)
STEMCELL Technologies, Inc. (Canada)

8. GLOBAL MARKET PERSPECTIVE

Table 6. World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 7. World Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 8. World 14-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
US Diagnostics Market: An Overview
CTC Diagnostics in the US – Set for a Strong Growth
Approved CTC Tests in the US – A Brief Comparison
Cancer Incidence in the US

Table 9. New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)

Table 10. Cancer Related Deaths by Gender in the US (2017E) (includes corresponding Graph/Chart)

Research Breakthroughs in the US CTC Market
Product Launches
Strategic Corporate Developments
Select Players
B. Market Analytics

Table 11. The US Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 12. The US Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis
Current and Future Analysis
Canadian Cancer Statistics

Table 13. New Cancer Cases in Canada (2016): Percentage Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart)

Table 14. New Cancer Cases in Canada by Province (2016) (includes corresponding Graph/Chart)

Table 15. Cancer Incidence in Canada by Age Group and Gender: Age Standardized Incidence Rate per 100,000 People (2015) (includes corresponding Graph/Chart)

Stemcell Technologies, Inc. – A Key Player
B. Market Analytics

Table 16. Canadian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 17. Canadian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. JAPAN

Market Analysis

Table 18. Japanese Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 19. Japanese Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Current & Future Analysis
Insight into Molecular Diagnostics Markets in Europe
Cancer Trends

Table 20. Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)

B. Market Analytics

Table 21. European Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 22. European Historic Review for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

Table 23. European 14-Year Perspective for Circulating Tumor Cell (CTC) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Current & Future Analysis
ScreenCell – A Key Player
B. Market Analytics

Table 24. French Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 25. French Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Current & Future Analysis
An Overview of Molecular Diagnostics Market
Strategic Corporate Development
Key Player
B. Market Analytics

Table 26. German Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 27. German Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4C. ITALY

A. Market Analysis
Current & Future Analysis
Rarecells Sas – A Key Player
B. Market Analytics

Table 28. Italian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 29. Italian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4D. THE UNITED KINGDOM

Market Analysis

Table 30. The UK Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 31. The UK Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4E. SPAIN

Market Analysis

Table 32. Spanish Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 33. Spanish Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4F. RUSSIA

Market Analysis

Table 34. Russian Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 35. Russian Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

Market Analysis

Table 36. Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 37. Rest of Europe Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Current & Future Analysis
Cancer Trends in Asia-Pacific

Table 38. Cancer Incidence in Asia-Oceania by Site: 2011 (in Thousands) (includes corresponding Graph/Chart)

Indian Molecular Diagnostics Market
China
Strategic Corporate Development
Key Player
B. Market Analytics

Table 41. Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 42. Asia-Pacific Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

6. REST OF WORLD

A. Market Analysis
Current & Future Analysis
Key Player
B. Market Analytics

Table 43. Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 Through 2022 (includes corresponding Graph/Chart)

Table 44. Rest of World Historic Review for Circulating Tumor Cell (CTC) Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled:
The United States (31)
Canada (3)
Europe (10)
  France (1)
  Germany (6)
  The United Kingdom (2)
  Italy (1)
Asia-Pacific (Excluding Japan) (3)
Middle East (1)